ERBB2 and breast carcinoma: The combination of eribulin, trastuzumab, and pertuzumab, followed by maintenance with trastuzumab and pertuzumab until disease progression or unacceptable toxicity, may be considered a valid alternative to the standard regimen of taxane, trastuzumab, and pertuzumab in patients with metastatic HER2-positive breast cancer (expert recommendation).